Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

In the last two decades, multi (MDR), extensively (XDR), extremely (XXDR) and total (TDR)
drug-resistant Mycobacterium tuberculosis (M. tb) strains have emerged as a threat to public …

Mycobacterium tuberculosis (Mtb) infection is notoriously difficult to treat. Treatment efficacy
is limited by Mtb's intrinsic drug resistance, as well as its ability to evolve acquired resistance …

Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in
containing the global tuberculosis epidemic. Mycobacterium tuberculosis is intrinsically …

Abstract Drug-resistant TB (DR-TB) remains a significant challenge in TB treatment and
control programmes worldwide. Advances in sequencing technology have significantly …

Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment
of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously …

Abstract Treatment of tuberculosis (TB) has been a therapeutic challenge because of not
only the naturally high resistance level of Mycobacterium tuberculosis to antibiotics but also …

The growing number of bacterial pathogens that are resistant to numerous antibiotics is a
cause for concern around the globe. There have been no new broad‐spectrum antibiotics …

Tuberculosis (TB) has become a curable disease, thanks to the discovery of antibiotics.
However, it has remained one of the most difficult infections to treat. Most current TB …

Multidrug efflux pumps are chromosomally encoded genetic elements capable of mediating
resistance to toxic compounds in several life forms. In bacteria, these elements are involved …